A citation-based method for searching scientific literature


List of co-cited articles
9 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer.
Melinda L Telli, Kirsten M Timms, Julia Reid, Bryan Hennessy, Gordon B Mills, Kristin C Jensen, Zoltan Szallasi, William T Barry, Eric P Winer, Nadine M Tung,[...]. Clin Cancer Res 2016
353
100

Allele-specific copy number analysis of tumors.
Peter Van Loo, Silje H Nordgard, Ole Christian Lingjærde, Hege G Russnes, Inga H Rye, Wei Sun, Victor J Weigman, Peter Marynen, Anders Zetterberg, Bjørn Naume,[...]. Proc Natl Acad Sci U S A 2010
590
66

Pan-cancer landscape of homologous recombination deficiency.
Luan Nguyen, John W M Martens, Arne Van Hoeck, Edwin Cuppen. Nat Commun 2020
46
66

Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer.
V Abkevich, K M Timms, B T Hennessy, J Potter, M S Carey, L A Meyer, K Smith-McCune, R Broaddus, K H Lu, J Chen,[...]. Br J Cancer 2012
328
66

Absolute quantification of somatic DNA alterations in human cancer.
Scott L Carter, Kristian Cibulskis, Elena Helman, Aaron McKenna, Hui Shen, Travis Zack, Peter W Laird, Robert C Onofrio, Wendy Winckler, Barbara A Weir,[...]. Nat Biotechnol 2012
66

Ploidy and large-scale genomic instability consistently identify basal-like breast carcinomas with BRCA1/2 inactivation.
Tatiana Popova, Elodie Manié, Guillaume Rieunier, Virginie Caux-Moncoutier, Carole Tirapo, Thierry Dubois, Olivier Delattre, Brigitte Sigal-Zafrani, Marc Bollet, Michel Longy,[...]. Cancer Res 2012
299
66

Telomeric allelic imbalance indicates defective DNA repair and sensitivity to DNA-damaging agents.
Nicolai J Birkbak, Zhigang C Wang, Ji-Young Kim, Aron C Eklund, Qiyuan Li, Ruiyang Tian, Christian Bowman-Colin, Yang Li, April Greene-Colozzi, J Dirk Iglehart,[...]. Cancer Discov 2012
249
66

Clinical assays for assessment of homologous recombination DNA repair deficiency.
Elizabeth H Stover, Katherine Fuh, Panagiotis A Konstantinopoulos, Ursula A Matulonis, Joyce F Liu. Gynecol Oncol 2020
13
66

Pan-cancer analysis of genomic scar signatures associated with homologous recombination deficiency suggests novel indications for existing cancer drugs.
Andrea M Marquard, Aron C Eklund, Tejal Joshi, Marcin Krzystanek, Francesco Favero, Zhigang C Wang, Andrea L Richardson, Daniel P Silver, Zoltan Szallasi, Nicolai J Birkbak. Biomark Res 2015
104
66


The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial.
Shahneen K Sandhu, William R Schelman, George Wilding, Victor Moreno, Richard D Baird, Susana Miranda, Lucy Hylands, Ruth Riisnaes, Martin Forster, Aurelius Omlin,[...]. Lancet Oncol 2013
355
33

Dissociation of p53-mediated suppression of homologous recombination from G1/S cell cycle checkpoint control.
H Willers, E E McCarthy, B Wu, H Wunsch, W Tang, D G Taghian, F Xia, S N Powell. Oncogene 2000
86
33

Chromosomes, sex chromatin, and cancer.
M L BARR, K L MOORE. Proc Can Cancer Conf 1957
21
33

DNA damage response protein TOPBP1 regulates X chromosome silencing in the mammalian germ line.
Elias ElInati, Helen R Russell, Obah A Ojarikre, Mahesh Sangrithi, Takayuki Hirota, Dirk G de Rooij, Peter J McKinnon, James M A Turner. Proc Natl Acad Sci U S A 2017
14
33

Phase I, Dose-Escalation, Two-Part Trial of the PARP Inhibitor Talazoparib in Patients with Advanced Germline BRCA1/2 Mutations and Selected Sporadic Cancers.
Johann de Bono, Ramesh K Ramanathan, Lida Mina, Rashmi Chugh, John Glaspy, Saeed Rafii, Stan Kaye, Jasgit Sachdev, John Heymach, David C Smith,[...]. Cancer Discov 2017
214
33


Tumour lineage shapes BRCA-mediated phenotypes.
Philip Jonsson, Chaitanya Bandlamudi, Michael L Cheng, Preethi Srinivasan, Shweta S Chavan, Noah D Friedman, Ezra Y Rosen, Allison L Richards, Nancy Bouvier, S Duygu Selcuklu,[...]. Nature 2019
133
33

The Cancer Genome Atlas: Creating Lasting Value beyond Its Data.
Carolyn Hutter, Jean Claude Zenklusen. Cell 2018
191
33

DNA repair pathway gene expression score correlates with repair proficiency and tumor sensitivity to chemotherapy.
Sean P Pitroda, Itai M Pashtan, Hillary L Logan, Brian Budke, Thomas E Darga, Ralph R Weichselbaum, Philip P Connell. Sci Transl Med 2014
57
33

SMCHD1 promotes ATM-dependent DNA damage signaling and repair of uncapped telomeres.
Aleksandra Vančevska, Wareed Ahmed, Verena Pfeiffer, Marianna Feretzaki, Simon J Boulton, Joachim Lingner. EMBO J 2020
7
33

Signatures of mutational processes in human cancer.
Ludmil B Alexandrov, Serena Nik-Zainal, David C Wedge, Samuel A J R Aparicio, Sam Behjati, Andrew V Biankin, Graham R Bignell, Niccolò Bolli, Ake Borg, Anne-Lise Børresen-Dale,[...]. Nature 2013
33


Homologous Recombination Repair Deficiency and the Immune Response in Breast Cancer: A Literature Review.
B Pellegrino, A Musolino, A Llop-Guevara, V Serra, P De Silva, Z Hlavata, D Sangiolo, K Willard-Gallo, C Solinas. Transl Oncol 2020
20
33

A role for the p53 tumour suppressor in regulating the balance between homologous recombination and non-homologous end joining.
Sylvie Moureau, Janna Luessing, Emma Christina Harte, Muriel Voisin, Noel Francis Lowndes. Open Biol 2016
18
33

A mutational signature reveals alterations underlying deficient homologous recombination repair in breast cancer.
Paz Polak, Jaegil Kim, Lior Z Braunstein, Rosa Karlic, Nicholas J Haradhavala, Grace Tiao, Daniel Rosebrock, Dimitri Livitz, Kirsten Kübler, Kent W Mouw,[...]. Nat Genet 2017
228
33



Inhibition of Atm and/or Atr disrupts gene silencing on the inactive X chromosome.
Yan Ouyang, Jennifer Salstrom, Silvia Diaz-Perez, Shareef Nahas, Youko Matsuno, David Dawson, Michael A Teitell, Steve Horvath, Arthur D Riggs, Richard A Gatti,[...]. Biochem Biophys Res Commun 2005
10
33

Homologous recombination deficiency (HRD) score in germline BRCA2- versus ATM-altered prostate cancer.
Tamara L Lotan, Harsimar B Kaur, Daniela C Salles, Sanjana Murali, Edward M Schaeffer, Jerry S Lanchbury, William B Isaacs, Robert Brown, Andrea L Richardson, Olivier Cussenot,[...]. Mod Pathol 2021
7
33

Correlation of homologous recombination deficiency induced mutational signatures with sensitivity to PARP inhibitors and cytotoxic agents.
Ádám Póti, Hella Gyergyák, Eszter Németh, Orsolya Rusz, Szilárd Tóth, Csenger Kovácsházi, Dan Chen, Bernadett Szikriszt, Sándor Spisák, Shunichi Takeda,[...]. Genome Biol 2019
33
33

Cancer Incidence in BRCA1 mutation carriers.
Deborah Thompson, Douglas F Easton. J Natl Cancer Inst 2002
728
33

HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures.
Helen Davies, Dominik Glodzik, Sandro Morganella, Lucy R Yates, Johan Staaf, Xueqing Zou, Manasa Ramakrishna, Sancha Martin, Sandrine Boyault, Anieta M Sieuwerts,[...]. Nat Med 2017
354
33

Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase.
Helen E Bryant, Niklas Schultz, Huw D Thomas, Kayan M Parker, Dan Flower, Elena Lopez, Suzanne Kyle, Mark Meuth, Nicola J Curtin, Thomas Helleday. Nature 2005
33

Tumor mutation burden forecasts outcome in ovarian cancer with BRCA1 or BRCA2 mutations.
Nicolai Juul Birkbak, Bose Kochupurakkal, Jose M G Izarzugaza, Aron C Eklund, Yang Li, Joyce Liu, Zoltan Szallasi, Ursula A Matulonis, Andrea L Richardson, J Dirk Iglehart,[...]. PLoS One 2013
98
33

BRCA locus-specific loss of heterozygosity in germline BRCA1 and BRCA2 carriers.
Kara N Maxwell, Bradley Wubbenhorst, Brandon M Wenz, Daniel De Sloover, John Pluta, Lyndsey Emery, Amanda Barrett, Adam A Kraya, Ioannis N Anastopoulos, Shun Yu,[...]. Nat Commun 2017
116
33

Pan-Cancer Analysis of BRCA1 and BRCA2 Genomic Alterations and Their Association With Genomic Instability as Measured by Genome-Wide Loss of Heterozygosity.
Ethan S Sokol, Dean Pavlick, Hossein Khiabanian, Garrett M Frampton, Jeffrey S Ross, Jeffrey P Gregg, Primo N Lara, Steffi Oesterreich, Neeraj Agarwal, Andrea Necchi,[...]. JCO Precis Oncol 2020
25
33

Regulation and pharmacological targeting of RAD51 in cancer.
McKenzie K Grundy, Ronald J Buckanovich, Kara A Bernstein. NAR Cancer 2020
12
33

BRCAness revisited.
Christopher J Lord, Alan Ashworth. Nat Rev Cancer 2016
585
33

International network of cancer genome projects.
Thomas J Hudson, Warwick Anderson, Axel Artez, Anna D Barker, Cindy Bell, Rosa R Bernabé, M K Bhan, Fabien Calvo, Iiro Eerola, Daniela S Gerhard,[...]. Nature 2010
33

Cancer Surveillance in Healthy Carriers of Germline Pathogenic Variants in BRCA1/2: A Review of Secondary Prevention Guidelines.
Boudewijn Dullens, Robin de Putter, Matteo Lambertini, Angela Toss, Sileny Han, Els Van Nieuwenhuysen, Toon Van Gorp, Adriaan Vanderstichele, Chantal Van Ongeval, Machteld Keupers,[...]. J Oncol 2020
6
33

Human genes escaping X-inactivation revealed by single cell expression data.
Kerem Wainer Katsir, Michal Linial. BMC Genomics 2019
24
33

Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1.
David A Barbie, Pablo Tamayo, Jesse S Boehm, So Young Kim, Susan E Moody, Ian F Dunn, Anna C Schinzel, Peter Sandy, Etienne Meylan, Claudia Scholl,[...]. Nature 2009
33

Two genetic hits (more or less) to cancer.
A G Knudson. Nat Rev Cancer 2001
620
33

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy.
Hannah Farmer, Nuala McCabe, Christopher J Lord, Andrew N J Tutt, Damian A Johnson, Tobias B Richardson, Manuela Santarosa, Krystyna J Dillon, Ian Hickson, Charlotte Knights,[...]. Nature 2005
33

PARP Inhibitors in Metastatic Prostate Cancer: Evidence to Date.
Emily Nizialek, Emmanuel S Antonarakis. Cancer Manag Res 2020
17
33

Pathological chemotherapy response score is prognostic in tubo-ovarian high-grade serous carcinoma: A systematic review and meta-analysis of individual patient data.
Paul A Cohen, Aime Powell, Steffen Böhm, C Blake Gilks, Colin J R Stewart, Tarek M Meniawy, Max Bulsara, Stefanie Avril, Eleanor C Brockbank, Tjalling Bosse,[...]. Gynecol Oncol 2019
30
33

Prognostic significance of tumor-infiltrating T-lymphocytes in primary and metastatic lesions of advanced stage ovarian cancer.
Ninke Leffers, Marloes J M Gooden, Renske A de Jong, Baukje-Nynke Hoogeboom, Klaske A ten Hoor, Harry Hollema, H Marieke Boezen, Ate G J van der Zee, Toos Daemen, Hans W Nijman. Cancer Immunol Immunother 2009
267
33

The Application of Patient-Derived Xenograft Models in Gynecologic Cancers.
Wenxiao Jiang, Shangdan Xie, Yi Liu, Shuangwei Zou, Xueqiong Zhu. J Cancer 2020
2
50

Ovarian cancer statistics, 2018.
Lindsey A Torre, Britton Trabert, Carol E DeSantis, Kimberly D Miller, Goli Samimi, Carolyn D Runowicz, Mia M Gaudet, Ahmedin Jemal, Rebecca L Siegel. CA Cancer J Clin 2018
33

RECIST 1.1 criteria predict recurrence-free survival in advanced ovarian cancer submitted to neoadjuvant chemotherapy.
Giorgio Bogani, Laura Matteucci, Stefano Tamberi, Antonino Ditto, Ilaria Sabatucci, Ferdinando Murgia, Valentina Arcangeli, Giuseppa Maltese, Giuseppe Comerci, Marco Stefanetti,[...]. Eur J Obstet Gynecol Reprod Biol 2019
6
33


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.